News

Skyrizi and Rinvoq Propel AbbVie's Q4 Revenue Surge, Signaling Robust Immunology Future

Araverus Team|Wednesday, February 4, 2026 at 1:34 PM

Araverus Team

Feb 4, 2026 · 1:34 PM

AbbVie · Earnings · Immunology Drugs · Revenue Growth

AbbVie Earnings Immunology Drugs Revenue Growth

AbbVie reported higher fourth-quarter revenue driven by strong demand for its immunology drugs Skyrizi and Rinvoq, while also experiencing a smaller decline in sales of its older drug Humira.

Read More On

AbbVie Revenue Rises on Immunology Growthwsj.com

AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs By Reuters - Investing.cominvesting.com

AbbVie touts 'record' sales amid uneven quarter for immunology stars - FirstWord Pharmafirstwordpharma.com

AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs - marketscreener.commarketscreener.com

Skyrizi and Rinvoq Propel AbbVie's Q4 Revenue Surge, Signaling Robust Immunology Future

Read More On

Related Articles

Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products

Biogen Revenue Down as Multiple Sclerosis Sales Slide

Boston Scientific Profit, Sales Rise but Issues Soft Guidance

Innovent Biologics Strikes Partnership Deal With Eli Lilly

Skyrizi and Rinvoq Propel AbbVie's Q4 Revenue Surge, Signaling Robust Immunology Future

Read More On

Related Articles

Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products

Biogen Revenue Down as Multiple Sclerosis Sales Slide

Boston Scientific Profit, Sales Rise but Issues Soft Guidance

Innovent Biologics Strikes Partnership Deal With Eli Lilly